Form 8-K - Current report:
SEC Accession No. 0001628280-26-052527
Filing Date
2026-08-04
Accepted
2026-08-04 16:03:32
Documents
13
Period of Report
2026-08-04
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K pcrx-20260804.htm   iXBRL 8-K 24936
2 EX-99.1 pcrx-06302026x991.htm EX-99.1 369452
6 PACIRA BIOSCIENCES LOGO paciralogoa.jpg GRAPHIC 468777
  Complete submission text file 0001628280-26-052527.txt   1143819

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT pcrx-20260804.xsd EX-101.SCH 1792
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT pcrx-20260804_lab.xml EX-101.LAB 21880
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT pcrx-20260804_pre.xml EX-101.PRE 12518
16 EXTRACTED XBRL INSTANCE DOCUMENT pcrx-20260804_htm.xml XML 2734
Mailing Address 2000 SIERRA POINT PARKWAY SUITE 900 BRISBANE CA 94005
Business Address 2000 SIERRA POINT PARKWAY SUITE 900 BRISBANE CA 94005 650-242-8052
Pacira BioSciences, Inc. (Filer) CIK: 0001396814 (see all company filings)

EIN.: 510619477 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35060 | Film No.: 261238438
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)